If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT01329783","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"EuroSIDA sub-cohort","arm_group_description":"HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)","arm_type":""}],"assignment":"","brief_summary":"Human Immunodeficiency Virus (HIV) infected patients who meet the entry criteria for the maraviroc pivotal trials (Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients, MOTIVATE) will be identified from the EuroSIDA HIV cohort. The rates of specific clinical adverse events in this identified patient population will be compared with the rates of these events in the participants of the MOTIVATE trials.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"EuroSIDA As An External Comparator To MOTIVATE Trials","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV","LookupValue_OneLinkTx":""},{"DisplayValue":"Immune, Inflammatory & Infections - Other","DisplayValue_OneLinkTx":"","InternalValue":"CON_IMMUNE_OTHER","LookupValue":"AIDS","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:05:14","criteria":"Inclusion Criteria: - Patient aged over 16 at baseline. - Viral Load (VL) > 5000 copies/ml at baseline (and measured in 6 months prior to baseline). - No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or on no ARVs in the month prior to baseline. - > 3 months exposure (sequential or cumulative) to at least 3 of the following; - Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) - Non-nucleoside reverse transcriptase inhibitor (NNNRTI) - Protease Inhibitor (PI ) - Enfuvirtide Exclusion Criteria: None","detailed_description":"All patients in EuroSIDA cohort that meet the entry criteria of MOTIVATE trials are included without any sampling.","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"1181","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"d7f02327-5756-5859-9992-377245d6f614","internal":{"content":null,"contentDigest":"d91b113018d5c5c0d8215bbe7cef244c","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Patient aged over 16 at baseline. - Viral Load (VL) > 5000 copies/ml at baseline (and measured in 6 months prior to baseline). - No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or on no ARVs in the month prior to baseline. - > 3 months exposure (sequential or cumulative) to at least 3 of the following; - Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) - Non-nucleoside reverse transcriptase inhibitor (NNNRTI) - Protease Inhibitor (PI ) - Enfuvirtide Exclusion Criteria: None","interventions":[{"arm_group_label":"EuroSIDA sub-cohort","intervention_description":"No intervention is distributed during this trial.","intervention_name":"maraviroc","intervention_type":"Other"}],"interventional_subtype":"","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"03/01/2011 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001104&StudyName=EuroSIDA%20As%20An%20External%20Comparator%20To%20MOTIVATE%20Trials"}],"locations":[],"masking":"","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"16","minimum_age_raw":"16 Years","modified_date":"10/01/2018 22:57:14","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"1","observational_study_design":"Cohort","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Incidence And Risk Factors For Acquired Immune Deficiency Syndrome (AIDS) Defining And Non-AIDS Defining Malignancies, And Other AIDS Defining Illnesses In The EuroSIDA Study","org_study_id":"A4001104","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"03/01/2011 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Malignancy","outcome_time_frame":"Median follow up of 3 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Opportunistic infection","outcome_time_frame":"Median follow up of 3 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Myocardial infarction","outcome_time_frame":"Median follow up of 3 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"All cause death","outcome_time_frame":"Median follow up of 3 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Liver related death","outcome_time_frame":"Median follow up of 3 years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Copenhagen HIV Programme","Pfizer"]},"start_date":"04/01/2007 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":false}},"pageContext":{"studyId":"A4001104"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}